Sunday, 20 September 2026European Markets

CEGEDIM And EQUASENS Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - cegedim (cgm.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
cegedim (cgm.pa) €19.12 2.6% 5.08%
equasens (eqs.pa) €76.10 1.47% 28.59%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. cegedim (cgm.pa)

2.6% forward dividend yield and 5.08% return on equity

cegedim sa operates as a technology and services company in the digital data flow management for healthcare ecosystem and b2b, and business software publisher for healthcare and insurance professionals worldwide. it operates in two divisions, health insurance, hr and e-services; and healthcare professionals. the health insurance, hr and e-services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. this division also provides solutions for hosting, hr and payroll management outsourcing, and electronic data exchange services. the healthcare professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. the company was incorporated in 1969 and is headquartered in boulogne-billancourt, france. cegedim sa is a subsidiary of fcb sa.

earnings per share

as for profitability, cegedim has a trailing twelve months eps of €1.

pe ratio

cegedim has a trailing twelve months price to earnings ratio of 19.12. meaning, the purchaser of the share is investing €19.12 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.08%.

yearly top and bottom value

cegedim's stock is valued at €19.12 at 07:30 est, way under its 52-week high of €25.00 and way above its 52-week low of €13.56.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cegedim's stock is considered to be oversold (<=20).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.6%.

revenue growth

year-on-year quarterly revenue growth grew by 5.2%, now sitting on 555.21m for the twelve trailing months.

more news about cegedim.

2. equasens (eqs.pa)

1.47% forward dividend yield and 28.59% return on equity

equasens société anonyme provides various it solutions for the healthcare sector in europe. it offers lgpi global services and officentral solutions for managing pharmacies and their networks; offimss, offisecure, offiprotect, offipass, offiseen, officash, offizzy, and offilocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising offitag, offitouch, offimédia, officonnect, automation systems, and customer loyalty programs. the company also provides my pilot, an analytics and management tool; offilearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, multimeds, automeds, and offitéléconsult, as well as pharmaceutical record and shared medical record services. in addition, it offers a ultimate, a system combining optimized pharmacy management and improved patient support; farmaclick, a protocol for communications between pharmacies and wholesalers-distributors; difarm, a solution for wholesalers-distributors; phare, a retail management tool; sophia, a pharmacy management application; offimédia pos display; enephro to enhance the care of chronic renal failure patients; and tpe pilot, a web-based application that simplifies the management and sharing of patient education programs. further, the company provides noviacare; carelib domicile; carelib ehpad; kapelse solutions; titan solutions; anthadine software and mobisoins mobile tool; microsoins, an in-home nursing care solution; and logiclic. additionally, it offers axigate solutions to manage the entire patient care pathway; chorus platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. the company was incorporated in 1996 and is based in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.

earnings per share

as for profitability, equasens has a trailing twelve months eps of €3.09.

pe ratio

equasens has a trailing twelve months price to earnings ratio of 24.63. meaning, the purchaser of the share is investing €24.63 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.59%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 30, 2022, the estimated forward annual dividend rate is 1.05 and the estimated forward annual dividend yield is 1.47%.

more news about equasens.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com